In a patient with multiple discrete round‑to‑oval ulcerated lesions on both lower legs (shins and ankles) that have central black necrotic crusts, surrounding hyperpigmentation, mildly raised violaceous borders, some healing lesions, and no improvement after amoxicillin and clindamycin, what is the most likely diagnosis and differential diagnoses, and which investigations (including skin biopsy and cultures) and evidence‑based treatment approach are recommended?

Most Likely Diagnosis: Pyoderma Gangrenosum

The clinical presentation—multiple discrete ulcerated lesions on bilateral lower legs with central black necrotic eschars, violaceous borders, surrounding hyperpigmentation, and failure to respond to amoxicillin and clindamycin—is most consistent with pyoderma gangrenosum (PG). 1

Clinical Reasoning

The key diagnostic features that point toward PG include:

• Location: Shins and ankles are the most common sites for PG 1
• Morphology: Violaceous undermined borders with central necrosis are pathognomonic 1
• Antibiotic failure: Lack of response to standard antibiotics strongly suggests a non-infectious inflammatory process rather than bacterial infection 1
• Multiple discrete lesions: PG can present as single or multiple lesions 1

The presence of black necrotic crusts (eschars) with violaceous borders distinguishes this from simple bacterial infections like ecthyma, which typically responds to appropriate antibiotics.

Differential Diagnoses to Exclude

1. Ecthyma Gangrenosum

While the term "ecthyma" appears in your differential, ecthyma gangrenosum is distinctly different from common ecthyma. Ecthyma gangrenosum is a cutaneous vasculitis caused by bacterial invasion of vessel walls, classically associated with Pseudomonas aeruginosa in neutropenic or immunocompromised patients 2, 3, 2. Key distinguishing features:

• Occurs primarily in neutropenic/immunocompromised hosts 2
• Lesions preferentially occur between umbilicus and knees (groin, axilla, trunk) 3, 2
• Rapid progression (within 12-24 hours) 3
• Associated with systemic toxicity and fever 2

Your patient's one-month duration and lack of mentioned immunocompromise make this less likely.

2. Cutaneous Vasculitis

PG itself involves a form of vasculitis, but primary cutaneous vasculitis typically presents differently:

• Usually smaller, palpable purpura rather than large ulcers
• Different histopathology (leukocytoclastic vasculitis)
• Often associated with systemic symptoms

3. Atypical Infections

Consider fungal infections (Aspergillus, Mucor), atypical mycobacteria, or deep fungal infections 2, 4. However, the bilateral symmetric distribution and characteristic violaceous borders favor PG over infection.

Diagnostic Investigations

PG is fundamentally a diagnosis of exclusion requiring systematic elimination of infectious and other causes. 1, 5

Essential Investigations:

1. Skin Biopsy (from lesion periphery, not center) 1, 5:

   • Histopathology shows non-specific findings (neutrophilic infiltrate, dermal necrosis)
   • Primary purpose is to exclude other diagnoses (vasculitis, infection, malignancy) 1
   • Avoid biopsy of necrotic center; sample the violaceous border

2. Bacterial Cultures 1:

   • Tissue culture (not just swab) from debrided ulcer base
   • Should be sterile unless secondary infection present 1
   • Include aerobic, anaerobic, and mycobacterial cultures

3. Fungal Studies:

   • Fungal culture and stains (PAS, GMS) 4
   • Consider if immunocompromised

4. Additional Testing:

   • Complete blood count (assess for neutropenia) 2
   • Inflammatory markers (ESR, CRP)
   • Screen for underlying systemic disease:
     • Inflammatory bowel disease (IBD) workup if GI symptoms present 1, 5
     • Rheumatologic panel if indicated
     • Hematologic evaluation (PG can associate with myeloproliferative disorders)

Common Diagnostic Pitfall:

PG is misdiagnosed in a substantial percentage of cases because clinicians pursue aggressive debridement or continue antibiotics without considering inflammatory dermatoses. 1 The pathergy phenomenon (worsening with trauma/surgery) can lead to deterioration if surgical debridement is attempted 5.

Evidence-Based Treatment Approach

First-Line Treatment:

Systemic corticosteroids are the traditional first-line therapy for PG. 1, 5

• Prednisone 0.5-1 mg/kg/day orally (typically 40-60 mg daily for adults)
• Continue until lesions show clear improvement, then taper gradually
• Response typically seen within 1-2 weeks 1

Second-Line/Refractory Cases:

If corticosteroids fail to achieve rapid response, infliximab should be considered. 1, 5

The 2016 ECCO guidelines emphasize that infliximab has changed PG management 5. A randomized controlled trial showed:

• 46% improvement with infliximab vs 6% with placebo at week 2 (p=0.025) 5
• Overall response rate of 69%, remission 31% at week 6 5
• Response rate >90% in patients with disease duration <12 weeks 5
• Response rate <50% in patients with disease >3 months 5

Infliximab dosing: 5 mg/kg IV at weeks 0,2, and 6, then every 8 weeks 1, 5

Alternative agents for refractory cases:

• Adalimumab 1
• Cyclosporine (oral or IV) 1, 5
• Tacrolimus (oral or IV) 1, 5
• Azathioprine (for maintenance or relapsing disease) 1

Topical Therapy:

• Topical corticosteroids (high-potency like clobetasol) 5
• Topical tacrolimus as alternative 5
• Appropriate wound care without aggressive debridement

Critical Treatment Principles:

1. Rapid healing should be the therapeutic goal because PG is debilitating 1, 5
2. Avoid surgical debridement due to pathergy phenomenon (trauma worsens lesions) 5
3. Discontinue ineffective antibiotics immediately 1
4. Treat underlying systemic disease if present (especially IBD) 1

Treatment Algorithm:

For your patient with one-month duration:

1. Immediate: Start prednisone 0.5-1 mg/kg/day + topical clobetasol
2. Week 2 assessment:
   • If significant improvement → continue corticosteroids with gradual taper
   • If inadequate response → add or switch to infliximab 5 mg/kg
3. Week 6 assessment:
   • If still refractory → consider cyclosporine or alternative immunosuppression
   • If improving → continue therapy and plan maintenance strategy

Duration of Treatment:

• Acute therapy: 7-14 days to achieve control 2
• Maintenance: May require months of immunosuppression
• PG has >25% recurrence rate, often at same site 1

Special Considerations:

In chronic cases with extensive scarring and treatment resistance (not typical for your one-month presentation), address potential comorbid factors 6:

• Vascular insufficiency from chronic inflammation
• Necrotic debris requiring gentle removal
• Excessive wound fluid management
• Consider pentoxifylline, compression therapy, and cadexomer iodine 6

Key Clinical Pearls:

• The combination of violaceous borders, necrotic centers, shin location, and antibiotic failure is virtually diagnostic of PG 1
• Biopsy confirms diagnosis by exclusion, not by specific findings 1
• Earlier treatment (disease <3 months) predicts better response to biologics 5
• Never perform aggressive surgical debridement—pathergy will worsen lesions 1, 5
• Screen for IBD and other systemic associations 1, 5